Breakthrough Blood Test Detects Elusive Endometriosis; Promising Drug for ALS Progresses

A new blood test developed by HerAnova Lifesciences has shown promising results in detecting endometriosis, often missed by traditional imaging methods such as ultrasounds and MRIs. Additionally, an experimental drug PrimeC is showing potential for treating ALS, according to recent trials emphasizing safety and improved functional outcomes.

A groundbreaking blood test is reshaping diagnosis for endometriosis, a uterine disorder affecting numerous women, by detecting cases missed by ultrasounds and MRIs. The test was found to accurately identify 80% of confirmed cases and correctly rule out the disease in 97.5% of uninfected individuals, presenting a less invasive alternative to current surgical methods.

HerAnova Lifesciences, the test's developer, noted it identified 61.5% of cases overlooked by traditional imaging, signifying a major leap forward in diagnostic capability. The results, published in the Journal of Minimally Invasive Gynecology, will be showcased at the American & Global College of Endometriosis Specialists Annual Meeting in Las Vegas.

Separately, a mid-stage trial for PrimeC indicates the drug could be essential for ALS, showing added benefits in speech and swallowing functionality. Developed by NeuroSense Therapeutics and Recipharm, this combination of celecoxib and ciprofloxacin focuses on ALS-associated neuroinflammation and offers a promising new pathway for treatment, paving the way for an expansive Phase 3 study.

(With inputs from agencies.)